Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial

被引:40
|
作者
Leite de Fornasari, Margareth Lage [1 ]
dos Santos Sens, Yvoty Alves [2 ]
机构
[1] Sch Med Sci, Post Graduat Hlth Sci, Div Santa Casa Sao Paulo, Sao Paulo, Brazil
[2] Nephron Grp, Substitut Renal Therapy, Sao Paulo, SP, Brazil
关键词
CHRONIC KIDNEY-DISEASE; DIETARY-PROTEIN INTAKE; HEMODIALYSIS-PATIENTS; HEALTH IMPACT; HYPERPHOSPHATEMIA; MORTALITY; METABOLISM; GUIDELINES; MANAGEMENT; SURVIVAL;
D O I
10.1053/j.jrn.2016.08.009
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objective: The purpose of the study was to verify the effects of replacing phosphorus-containing food additives with foods without additives on phosphatemia in end-stage renal disease (ESRD) patients. Design: Randomized clinical trial. Setting: Adult patients on hemodialysis for >= 6 months at a single center. Subjects: A total of 134 patients with phosphorus levels of. 5.5 mg/dL were included and were randomized into an intervention group (n 5 67) and a control group (n 5 67). Intervention: The IG received individual orientation to replace processed foods that have phosphorus additives with foods of similar nutritional value without these additives. The CG received only the nutritional orientation given before the study. Clinical laboratory data, nutritional status, energy and protein intake, and normalized protein nitrogen appearance (nPNA) were evaluated at the beginning of the study and after 90 days. Results: There was no initial difference between the groups in terms of serum phosphorus levels, nutritional status, and energy intake. After 3 months, there was a decline in phosphorus levels in the IG (from 7.2 +/- 1.4 to 5.0 +/- 1.3 mg/dL, P < .001), but there was no significant difference in the CG (from 7.1 +/- 1.2 to 6.7 +/- 1.2 mg/dL, P =.65). In the IG, 69.7% of the patients reached the serum phosphorus target of <= 5.5 mg/dL; however, only 18.5% of the CG subjects reached this level (P,.001). Conclusion: At the end, there was no difference between the two groups in terms of nutritional status, energy intake, protein intake, and nPNA. The replacing phosphorus-containing food additives with foods without additives reduced serum phosphorus without interfering in the nutritional status of ESRD patients. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 32 条
  • [21] Effects of Nutritional Supplementation on Fatigue, and Autonomic and Immune Dysfunction in Patients with End-Stage Renal Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
    Fukuda, Sanae
    Koyama, Hidenori
    Kondo, Kazuhiro
    Fujii, Hisako
    Hirayama, Yoshinobu
    Tabata, Tsutomu
    Okamura, Mikio
    Yamakawa, Tomoyuki
    Okada, Shigeki
    Hirata, Sumio
    Kiyama, Hiroshi
    Kajimoto, Osami
    Watanabe, Yasuyoshi
    Inaba, Masaaki
    Nishizawa, Yoshiki
    PLOS ONE, 2015, 10 (03):
  • [22] Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of five different training interventions
    Ferrari, Filipe
    Helal, Lucas
    Dipp, Thiago
    Soares, Douglas
    Soldatelli, Angela
    Mills, Andrew Lee
    Paz, Claudio
    Tenorio, Mario Cesar Carvalho
    Motta, Marcelo Trotte
    Barcellos, Franklin Correa
    Stein, Ricardo
    JOURNAL OF NEPHROLOGY, 2020, 33 (02) : 251 - 266
  • [23] An Acetate-Buffered Balanced Crystalloid Versus 0.9% Saline in Patients with End-Stage Renal Disease Undergoing Cadaveric Renal Transplantation: A Prospective Randomized Controlled Trial
    Potura, Eva
    Lindner, Gregor
    Biesenbach, Peter
    Funk, Georg-Christian
    Reiterer, Christian
    Kabon, Barbara
    Schwarz, Christoph
    Druml, Wilfred
    Fleischmann, Edith
    ANESTHESIA AND ANALGESIA, 2015, 120 (01) : 123 - 129
  • [24] Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial
    Schneider, Andreas
    Schneider, Markus P.
    Krieter, Detlef H.
    Genser, Bernd
    Scharnagl, Hubert
    Stojakovic, Tatjana
    Wanner, Christoph
    Drechsler, Christiane
    PLOS ONE, 2015, 10 (05):
  • [25] Efficacy and Safety of Acupuncture for Restless Legs Syndrome in Patients with End-Stage Renal Disease: A Randomized-Controlled Trial at Hospital-Based Hemodialysis Center
    Chen, Jia-Ming
    Chang, Chia-Chu
    Li, Ya-Lun
    Chiu, Ping-Fang
    Chiang, John Y.
    Hsu, Po-Chi
    Lo, Lun-Chien
    JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE, 2024, 30 (10): : 978 - 985
  • [26] Constant Work-Rate Test to Assess the Effects of Intradialytic Aerobic Training in Mildly Impaired Patients With End-Stage Renal Disease: A Randomized Controlled Trial
    Reboredo, Maycon M.
    Neder, J. Alberto
    Pinheiro, Bruno V.
    Henrique, Diane M.
    Faria, Ruiter S.
    Paula, Rogerio B.
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2011, 92 (12): : 2018 - 2024
  • [27] Effects of neuromuscular electrical stimulation during hemodialysis on muscle strength, functional capacity and postural balance in patients with end-stage renal disease: a randomized controlled trial
    Machfer, Amal
    Fekih, Nadia
    Ammar, Achraf
    Hassen, Hayfa Ben Haj
    Daab, Wael
    Amor, Hassen Ibn Hadj
    Bouzid, Mohamed Amine
    Chtourou, Hamdi
    BMC NEPHROLOGY, 2025, 26 (01)
  • [28] Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: Microbial analysis from a randomized placebo-controlled trial
    Laffin, Michael R.
    Tayebi Khosroshahi, Hamid
    Park, Heekuk
    Laffin, Luke J.
    Madsen, Karen
    Kafil, Hossein Samadi
    Abedi, Behzad
    Shiralizadeh, Somayeh
    Vaziri, Nosratola D.
    HEMODIALYSIS INTERNATIONAL, 2019, 23 (03) : 343 - 347
  • [29] Early home-based group education to support informed decision-making among patients with end-stage renal disease: a multi-centre randomized controlled trial
    Massey, Emma K.
    Gregoor, Peter J. H. Smak
    Nette, Robert W.
    van den Dorpel, Marinus A.
    van Kooij, Anthony
    Zietse, Robert
    Zuidema, Willij C.
    Timman, Reinier
    Busschbach, Jan J.
    Weimar, Willem
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (05) : 823 - 830
  • [30] Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial
    Idorn, Thomas
    Knop, Filip K.
    Jorgensen, Morten B.
    Jensen, Tonny
    Resuli, Marsela
    Hansen, Pernille M.
    Christensen, Karl B.
    Holst, Jens J.
    Hornum, Mads
    Feldt-Rasmussen, Bo
    DIABETES CARE, 2016, 39 (02) : 206 - 213